Related Experiment Video
Updated: Apr 30, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Fibroblast growth factor 23 and uremic vascular calcification: is it time to escalate from biomarker status to
11] Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA [2] Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA [3] Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract:
Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Diabetic Nephropathy
Chronic Kidney Disease I: Introduction

